Access cutting-edge type 1 diabetes treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access type 1 diabetes specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related type 1 diabetes treatment provided free
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Check if you qualify for this type 1 diabetes clinical trial in Palo Alto, CA
If you're searching for type 1 diabetes treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced type 1 diabetes specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.